SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Sjögren Ingegerd)
 

Sökning: WFRF:(Sjögren Ingegerd) > (2015-2018) > Tumor Regression an...

Tumor Regression and Cure Depends on Sustained Th1 Responses

Dai, Min (författare)
University of Washington
Hellstrom, Ingegerd (författare)
University of Washington
Yip, Yuen Y. (författare)
University of Washington
visa fler...
Sjögren, Hans Olov (författare)
Lund University,Lunds universitet,Rausinglaboratoriet i Lund - Tumörsektionen,Forskargrupper vid Lunds universitet,Rausing laboratory of Lund - Tumor section,Lund University Research Groups
Hellstrom, Karl Erik (författare)
University of Washington
visa färre...
 (creator_code:org_t)
2018
2018
Engelska.
Ingår i: Journal of Immunotherapy. - 1524-9557. ; 41:8, s. 369-378
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • While immunomodulatory monoclonal antibodies (mAbs) have therapeutic efficacy against many tumors, few patients are cured. Attempting to improve their therapeutic efficacy we have applied the TC1 mouse lung carcinoma model and injected established subcutaneous tumors intratumorally with 3 weekly doses of various combinations of mAbs. Combinations of mAbs to CTLA4/PD1/CD137 (the 3 mAb combination) and to CTLA4/PD1/CD137/CD19 (the 4 mAb combination) were most efficacious to induce complete regression of both the injected tumor and an untreated tumor in the same mouse. Tumor cure was consistently associated with shifting a Th2 to a Th1 response in tumor-draining lymph nodes and spleen and it involved epitope specific and long-lived memory T cells as well as M1 macrophages. This shift and accompanying tumor rejection was harder to achieve as the treated tumors increased in size. Relapse of tumors which had initially regressed following treatment with immunomodulatory mAbs was associated with return of a Th2 microenvironment in tumors, tumor-draining lymph nodes and spleens rather than the emergence of immune-resistant tumor cells. While mAbs to CTLA4 plus PD-1 were therapeutically ineffective, combining the 2 of them with intraperitoneal cisplatin, 10 mg/kg, induced long-term complete tumor regression in most mice with small TC1 tumors and the therapeutic efficacy against larger tumors improved by administrating cisplatin together with the 3 or 4 mAb combination.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Immunology in the medical area (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

cisplatin
immunomodulatory antibodies
immunotherapy
tumor microenvironment

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy